An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations
研究概览
详细说明
The two sisters have a splicing mutation that is predicted to respond favorably to ivacaftor therapy. In addition to measurement of usual clinical outcomes (i.e. lung function, nutritional status), there is great interest on the impact on nontuberculous mycobacteria (NTM) airways infection.
Subjects will undergo sputum cultures at baseline and monthly during treatment, initially in the absence of anti-NTM therapy but with the intent to treat with antibiotics if there is persistence of the infection in cultures. Other clinical outcomes will include changes in sweat chloride, lung function and weight. Safety measures will include periodic assessment of liver enzymes. All serious and non-serious adverse events will be collected
研究类型
注册 (实际的)
阶段
- 第三阶段
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Subjects are >18 years of age and able to provide informed consent.
- Subjects reside in the US and are willing to be treated with ivacaftor.
- Subjects have the splicing mutation of interest.
- Subjects are willing and able to perform requirements of the study.
Exclusion Criteria:
- There are no relevant exclusion criteria for this n-of-2 study.
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：不适用
- 介入模型：单组作业
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：Ivacaftor
There is only one arm to this study.
The two sisters with Cystic Fibrosis will both receive Ivacaftor for 6 months for their treatment.
|
Subjects will be treated with ivacaftor for 6 months and followed for 7 months and will undergo assessments along the way to measure sweat chloride and sputum amounts.
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Forced Expiratory Volume
大体时间：24 weeks
|
Absolute change in percent predicted in 1 second FEV1 from baseline through week 24
|
24 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Sputum Results
大体时间：24 weeks
|
Achievement of mycobacterial culture conversion (negative culture)
|
24 weeks
|
|
Sweat Chloride
大体时间：24 Weeks
|
Testing efficacy through gathering absolute change in sweat chloride from baseline through week 24
|
24 Weeks
|
合作者和调查者
调查人员
- 首席研究员：Patrick A Flume, MD、Medical University of South Carolina
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.
Ivacaftor的临床试验
-
Charite University, Berlin, GermanyHannover Medical School; Heidelberg University; University of Giessen招聘中
-
Vertex Pharmaceuticals Incorporated完全的囊性纤维化美国, 英国, 德国, 西班牙, 瑞士, 加拿大, 荷兰, 意大利, 爱尔兰, 瑞典, 法国, 丹麦
-
University of California, Los AngelesUniversity of Iowa; Children's Hospital Colorado; University of Kansas Medical Center; University... 和其他合作者招聘中
-
Sonya HeltsheUniversity of Alabama at Birmingham; University of Washington; Cystic Fibrosis Foundation招聘中
-
Vertex Pharmaceuticals Incorporated完全的
-
Vertex Pharmaceuticals Incorporated完全的
-
Vertex Pharmaceuticals Incorporated完全的
-
Vertex Pharmaceuticals Incorporated完全的囊性纤维化美国, 西班牙, 爱尔兰, 比利时, 荷兰, 英国, 澳大利亚, 法国, 加拿大, 丹麦, 德国, 意大利, 以色列
-
Vertex Pharmaceuticals Incorporated完全的